The Bottom Line
- A crucial patent for continuous glucose monitoring technology has been upheld on appeal, creating significant market risk for competitors and potentially altering the competitive landscape.
- Businesses cannot rely on minor technical “workarounds” to avoid patent infringement; the Court of Appeal has reinforced a broader, “purposive” interpretation of patent claims.
- This decision strengthens the position of patent holders in the UK, demanding that CEOs and legal teams conduct rigorous Freedom to Operate (FTO) analyses before launching new tech products.
The Details
In a high-stakes legal battle between two giants of the medical technology world, the Court of Appeal has overturned a High Court decision in the patent dispute between Abbott and Dexcom. The case revolves around core technology used in modern continuous glucose monitoring (CGM) systems—a market defined by intense innovation and fierce competition. This judgment sends a clear signal to the technology and life sciences sectors about the robust nature of patent protection in the United Kingdom and has immediate commercial consequences for both parties.
The legal pivot point in this appeal was the principle of “purposive construction.” The High Court had initially taken a narrower, more literal view of the language in Abbott’s patent claims, finding that Dexcom’s competing product did not infringe. However, the Court of Appeal disagreed, adopting a broader perspective. It focused not just on the precise wording of the patent, but on what a person skilled in the relevant field would have understood the inventor to be protecting. By asking what the core purpose of the invention was, the court concluded that Dexcom’s device fell within the scope of Abbott’s patent, thereby reversing the initial finding of non-infringement.
For business leaders and in-house counsel, this outcome is a critical lesson in IP strategy. It serves as a stark reminder that designing a product to simply circumvent the literal text of a competitor’s patent is a high-risk strategy. Courts will look beyond semantic differences to the substance of the technology. For Abbott, this is a significant victory that solidifies its intellectual property and market position. For Dexcom and other innovators, it necessitates an urgent review of their product designs and IP risk assessments, underscoring that a proactive and commercially-minded IP strategy is non-negotiable in today’s tech-driven economy.
Source
Court of Appeal (Civil Division)
